Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Ohio Valley Health Center has reached a significant milestone with the successful completion of its first echocardiogram.This non-invasive ultrasound test, whic ...

Bleeding risk Omega-3 fatty acids are generally safe, but they can have side effects when consumed in high doses. One potential risk, as noted by the Cleveland Clinic, is an increased chance of ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...